Latest news with #preeclampsia
Yahoo
6 days ago
- Business
- Yahoo
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer
MINNEAPOLIS, August 06, 2025--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons. "We are pleased to welcome Dr. Krop to our executive leadership team," said Rick Pauls, President and CEO of DiaMedica. "Her extensive experience in the biopharma industry and track record of advancing innovative therapeutics from proof of concept to approval will be invaluable to our team as we advance toward late-stage clinical development of DM199. Additionally, Dr. Krop's previous experience in preeclampsia drug development will be beneficial as we work to provide a treatment for this significant unmet need. On behalf of the DiaMedica team, I thank Lorianne for her guidance and dedication, which helped position DiaMedica for success. We wish her the best in her future endeavors." Dr. Krop added, "I'm excited to join DiaMedica at such a pivotal time in its growth. DM199 has the potential to be a fully disease-modifying therapy for patients with preeclampsia, as demonstrated by the recent Phase 2 Part 1a interim trial results. I look forward to helping guide the company's clinical development strategy as we advance this first in class drug candidate into later stage development for both preeclampsia and acute ischemic stroke – two areas of urgent unmet need where no approved treatments currently exist." Dr. Krop has more than 20 years of experience as a strategic physician executive with leadership experience spanning multiple therapeutic and orphan indications in both pre-commercial and commercial organizations. She joins DiaMedica from PureTech Health, where she was CMO and Head of Development, leading multiple rare disease programs from preclinical development through Phase 2 trials. Prior, she served as CMO at Freeline Therapeutics, where she helped drive a successful IPO and oversaw three clinical stage gene therapy programs. Before that, Dr. Krop was CMO and Executive Vice President at AMAG Pharmaceuticals, where she was involved in the approval of three drugs and worked on the development of an orphan drug candidate for the treatment of severe preeclampsia. Previously, Dr. Krop has held senior development roles at Vertex Pharmaceuticals, Stryker Regenerative Medicine, Peptimmune, Millennium Pharmaceuticals, and Pfizer. Dr. Krop received her MD from Brown University School of Medicine and completed her internal medicine residency at Georgetown University Hospital. She also completed fellowships in epidemiology, clinical trial design and endocrinology at Johns Hopkins School of Medicine. Dr. Krop is board-certified in Endocrinology. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) In connection with Dr. Krop's appointment, DiaMedica granted her an inducement stock option to purchase 450,000 shares of DiaMedica's common stock pursuant to the DiaMedica Therapeutics, Inc. 2021 Employment Inducement Incentive Plan. The inducement grant was approved by the Company's compensation committee of the board of directors and will be effective as of Dr. Krop's first date of employment, August 11, 2025, and was a material inducement to her acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of her compensation. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management's current expectations. When used in this press release, the words "anticipates," "believes," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "seek," "might," "project," "target," "aim," or "will," the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding the Company's expectations regarding the anticipated clinical benefits and success of DM199 for the treatment of preeclampsia and acute ischemic stroke. Such statements and information reflect management's current view and DiaMedica undertakes no obligation to update or revise any of these statements or information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to the clinical expansion into preeclampsia and that trial; regulatory applications and related filing and approval timelines; the possibility of unfavorable results from DiaMedica's other ongoing or future clinical trials of DM199; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; the potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs and worldwide global supply chain disruptions on DiaMedica's business and clinical trials; DiaMedica's reliance on collaboration with third parties to conduct clinical trials; DiaMedica's ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for preeclampsia and acute ischemic stroke and the risks identified under the heading "Risk Factors" in DiaMedica's annual report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) and subsequent SEC reports, including DiaMedica's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws. View source version on Contacts Corporate Contact: Scott Kellen, Chief Financial Officer(763) 496-5118 | skellen@ Investor Contact: Mike Moyer, Managing Director, LifeSci Advisorsmmoyer@ Media Contact: Madelin Hawtin, LifeSci Communicationsmhawtin@ Sign in to access your portfolio
Globe and Mail
7 days ago
- Business
- Globe and Mail
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12 th. DiaMedica will host a live conference call on Wednesday, August 13 th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on the Company's website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until August 20, 2025, by dialing (888) 660-6345 (US Toll Free) and entering the replay passcode: 29006#. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at
The Guardian
22-07-2025
- Health
- The Guardian
Grace visited doctors with health concerns eight times in her last week of pregnancy. On the ninth visit, she was told her baby was stillborn
Grace* was just over 40 weeks pregnant when she arrived at a public hospital in regional New South Wales. The Gamilaraay woman had been excited for the pending birth of her first child, a son called Koa. Her husband's job meant he was often away for long stretches of time, but on this day, by chance, he was by her side attending her ultrasound for the first time. They were both waiting for the reassuring sounds of a heartbeat, a kick to the ribs to let her know her baby was OK. It didn't come. 'This was his first time seeing our baby on the ultrasound, but it was not a good one. That's when they told us that it was no heartbeat,' Grace says. 'He was gone.' It was Grace's ninth trip to the hospital after a flurry of presentations between her GP, local hospital and a larger major hospital where she had sought help with worrying symptoms. Her hands and feet became puffy at 39 weeks gestation; she was unable to wear her jewellery or watch. She'd had pains in her abdomen from undiagnosed gallstones earlier in her pregnancy but they were dismissed as indigestion. She visited her GP several times before being advised to go to the small local hospital. Each time her blood pressure was checked, she had given a urine sample and had been advised to go home. At 39 weeks gestation, she was advised against having her baby induced. One week later, her baby was confirmed to have died of complications from preeclampsia. After the ultrasound which revealed her son had died, Grace was given medication to bring on labour, told to go and get some dinner and come back to the hospital once contractions had started. 'We went back to the hospital and they gave us a room in the birthing suite away from the other mothers,' she says. She was in labour for two days. Grace strongly believes that if she had been listened to when she first began to seek medical attention, her son would be alive today. The day Grace speaks to Guardian Australia would have been Koa's ninth birthday. Instead, their only interaction was in a CuddleCot, a specialised cot with a cooling system to allow grieving families to spend time with their deceased baby. 'It's just really hard not to hear like that first cry, and your body just does strange things,' she says. 'He was laying in the little cot, I was looking at him, and just even though I knew, there was still some hope in me that his chest would move, or he'd start crying. I refused to believe what I was going through.' At those previous medical appointments, Grace says, her blood pressure readings were fluctuating 'dramatically', with some readings very high. She says she consistently showed elevated protein levels in her urine. Both are potential red flags for preeclampsia, a pregnancy complication which can be life-threatening for mother and baby. After three visits, between her GP and her local hospital, Grace was told by her obstetrician to present to another hospital two hours away, where she was monitored overnight before being discharged and told to go to her local GP. Her blood pressure at the GP clinic read 157/95, indicative of hypertension or preeclampsia. She was then told to go back to the local hospital to get her blood pressure rechecked – which yielded the same result. After half an hour her blood pressure dropped and she was told to go home and see her GP again the next day, and have her blood pressure checked every 48 hours. She says she was advised about decreased foetal movements, and told that her GP was against an induction and advised her to 'wait for the baby to be ready to come' – despite her pregnancy complications. She says a week after she was discharged – after eight visits to her GP and hospital with erratic and high blood pressure readings – she realised she hadn't felt the baby move, and so ate something to see if that would encourage movement. She said to her husband that she felt they weren't being listened to. 'I don't actually know what to do at this point,' she said. 'We go to the doctor, and they tell us to go to hospital. We go to the hospital, then they tell us to go back to the doctor, and it's just like a vicious cycle.' Grace called the maternity ward that had admitted her and was initially told to go to the local hospital before being advised to present to the maternity ward. She says she felt excited that she might get some help. Instead she was told her child was dead. 'There was no real time to process the news,' she says. 'I had to give natural birth and that [took] two days. They would not give me a C-section because they said that I would have mental problems from having to look at a scar on my stomach. But I still have problems from that experience. They treated me giving birth [to a dead baby] like a normal person who's having a live baby.' Guardian Australia has been investigating Aboriginal and Torres Strait Islander women's experiences in maternal care and midwifery, uncovering complaints of culturally unsafe care, allegations of discrimination, unwanted medical interventions and infant removals. Grace says she is unable to say if her Aboriginal heritage was a factor but strongly believes her concern that something was wrong was dismissed by both local doctors and the hospital. She sued NSW Health over the incident and the department settled without prejudice and with no admissions of liability. Her lawyer, Linda Crawford, a former midwife who now works for Catherine Henry Lawyers, claims Grace was let down by the medical system. 'There were many missed opportunities in the care provided to [her],' Crawford says. Crawford says she believes there is often a lack of appropriate expertise and medical experience in remote and regional areas that, coupled with the complex needs of patients and the vast areas that small local hospitals cover, can have adverse outcomes despite the best efforts of health professionals. In response to questions from Guardian Australia, NSW Health says it is 'committed to ensuring pregnant women, their babies and families receive high quality, safe and timely maternity care' but would not provide any further comment on Grace's case. 'We acknowledge the deep and lasting grief associated with the loss of a child and we extend our sincere condolences to all families impacted by stillbirth,' a NSW Health spokesperson said. Grace, who has since had two more children, says it is vital that women are listened to by health professionals and failure to do so can lead to devastating outcomes. 'All women need to be listened to,' she says. 'I just want the right treatment. I wanted to be heard and I wasn't.' *Names have been changed In Australia, the crisis support service Lifeline is 13 11 14. The Indigenous crisis hotline is 13 YARN, 13 92 76. Stillbirth support can be accessed via the Stillbirth Foundation Australia.
Yahoo
21-07-2025
- Business
- Yahoo
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline
MINNEAPOLIS, July 21, 2025--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced definitive agreements for a $30.1 million private placement of common shares led by current investors. No placement agent was engaged for this transaction. Pursuant to the terms of the securities purchase agreements, the Company will issue a total of 8,606,426 common shares at a purchase price of $3.50 per share. The private placement is expected to close on or about July 23, 2025, subject to the satisfaction of customary closing conditions. The capital raised is expected to fund the Company's operations for more than two years and support upcoming milestones including the submission of an investigational new drug (IND) application in the United States for preeclampsia and fetal growth restriction and a Phase 2b study to further evaluate DM199 in both indications, pending IND approval. "This financing allows us to rapidly accelerate our development efforts in preeclampsia and fetal growth restriction, both of which have no approved treatment options currently," said Rick Pauls, President and CEO of DiaMedica. "We believe DM199 has the potential to be a disease-modifying therapy for these patients, and look forward to building upon what is already the most advanced clinical program targeting these conditions." The offer and sale of the common shares in the private placement have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdiction's securities laws, and such common shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state and other securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the common shares issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the foregoing securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Required Canadian Related Party Transaction Disclosure DiaMedica has received binding commitments for participation in the private placement from certain non-management, related parties, in the aggregate amount of $30.1 million or 8,606,426 common shares. Accordingly, the private placement constitutes a "related party transaction" as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101") of the Canadian Securities Administrators. The private placement will be exempt from the valuation and the minority shareholder approval requirements of MI 61-101 under the exemptions contained in section 5.5(a) and 5.7(1)(a), respectively, as neither the fair market value of the common shares nor the fair market value of the consideration paid for the common shares insofar as it involves the related parties is more than 25% of the Company's market capitalization. About DM199 (rinvecalinase alfa) DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia, fetal growth restriction and acute ischemic stroke. KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that increases production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factor. In preeclampsia and fetal growth restriction, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta while for stroke intended to increase collateral circulation in the penumbra following a stroke. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management's current expectations. When used in this press release, the words "anticipates," "believes," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "seek," "might," "project," "target," "aim," or "will," the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding the Company's expectations regarding its expected cash runway and ability to obtain and complete a Phase 2b study in preeclampsia, the anticipated clinical benefits and success of DM199 for the treatment of preeclampsia and acute ischemic stroke, and the continued ReMEDy2 trial enrollment and the timing of the interim analysis on the first 200 participants in the first half of 2026. Such statements and information reflect management's current view and DiaMedica undertakes no obligation to update or revise any of these statements or information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to risks and uncertainties relating to the clinical expansion into preeclampsia and that trial; the timing of ReMEDy2 trial enrollment, regulatory applications and related filing and approval timelines; the possibility that enrollment in the ReMEDy2 trial will not continue to increase as anticipated; the possibility of additional future adverse events associated with or unfavorable results from the ReMEDy2 trial; the possibility of unfavorable results from DiaMedica's other ongoing or future clinical trials of DM199; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; DiaMedica's plans to develop, obtain regulatory approval for and commercialize its DM199 product candidate for the treatment of preeclampsia and acute ischemic stroke and its expectations regarding the benefits of DM199; DiaMedica's ability to conduct successful clinical testing of DM199 and within its anticipated parameters, site activations, enrollment numbers, costs and timeframes; the adaptive design of the ReMEDy2 trial and the possibility that the targeted enrollment and other aspects of the trial could change depending upon certain factors, including additional input from the FDA and the blinded interim analysis; the perceived benefits of DM199 over existing treatment options; the potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs and worldwide global supply chain shortages on DiaMedica's business and clinical trials, including its ability to meet its site activation and enrollment goals; DiaMedica's reliance on collaboration with third parties to conduct clinical trials; DiaMedica's ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for preeclampsia and acute ischemic stroke and the risks identified under the heading "Risk Factors" in DiaMedica's annual report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) and subsequent SEC reports. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws. View source version on Contacts Corporate Contact: Scott Kellen, Chief Financial Officer(763) 496-5118 | skellen@ Investor Contact: Mike Moyer, Managing Director, LifeSci Advisorsmmoyer@ Media Contact: Madelin Hawtin, LifeSci Communicationsmhawtin@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
21-07-2025
- Health
- Associated Press
4Kira4Dads to Host Second Dads Empowerment & Education In-Person Session: 'Calm Under Pressure'
'We look forward to reaching more dads and providing them with the information, resources, and network they need to be successful in their fatherhood journey through the maternal process.'— Charles Johnson, Founder of 4Kira4Moms ATLANTA, GA, UNITED STATES, July 21, 2025 / / -- 4Kira4Moms is proud to announce its second event, presented by its groundbreaking fatherhood initiative, 4Kira4Dads: Paternal Centers of Excellence (PCOE). On Saturday, August 2, 2025, from 10:00 AM to 1:00 PM EST, 'Calm Under Pressure' will help dads understand preeclampsia, blood pressure monitoring, self-care, and stress management. The PCOE in-person events are designed to equip fathers with the tools, knowledge, and confidence to support their partners during pregnancy and childbirth. This event is made possible with support from HOPE for Georgia Moms, reinforcing a shared mission to protect mothers and strengthen families through engaged, informed fatherhood. 'Our first event in the series, held in May, engaged many new and expectant dads,' said Charles Johnson, Founder of 4Kira4Moms. 'We look forward to reaching even more dads with our second session and providing them with the information, resources, and network they need to be successful in their fatherhood journey through the maternal process.' About the Event: 'Calm Under Pressure' will bring fathers together for powerful conversations, peer learning, and real-time coaching on how to be active, confident partners in maternal health. Participants will leave with a better understanding of how to advocate in healthcare settings and the practical ways to show up during pregnancy, delivery, and beyond. Additionally, the program will feature engaging activities and giveaways throughout its duration. Event Details: Date: Saturday, August 2, 2025 Time: 10:00 AM–1:00 PM Location: 4THPARK, 1526 E. Forest Avenue, Suite 102, East Point, CA 30344 Lunch will be provided, and free massages will be available. Our presenters include: ● Gabrielle Albert, Executive Director, 4Kira4Moms/4Kira4Dads ● Valerie Garcia, Director of Programs and Grants, 4Kira4Moms/4Kira4Dads ● Shana Scott - American Heart Association ● Cree Cunningham, LCSW, Healing Sacred Scars Holistic Wellness ● Ernie the Barber, Ernie's in the Cut ● Baba Isaiah Bryant, Malawi's House Transportation Assistance Available Upon Request Registration Link: 4Kira4Dads PCOE: Calm Under Pressure Following this event, the series will present the following sessions: ● August 30: Handling Your Business, featuring financial preparation and planning ● September 13: Post Game Prep, focusing on postpartum planning and support About 4Kira4Dads: An initiative of 4Kira4Moms, 4Kira4Dads: Paternal Centers of Excellence provides father-focused spaces ('locker rooms') that deliver healing, education, and advocacy training. From awareness to action, the program empowers dads to play an essential role in improving maternal outcomes. LaTricia H Woods Mahogany Xan Communications +1 480-374-1908 email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
